Licensing Agreement


Our attorneys represented Pfizer in a licensing agreement with Repligen for its spinal muscular atrophy (SMA) program. The program includes RG3039, a small molecule drug candidate in clinical development for SMA, as well as backup compounds and enabling technologies. Following Repligen’s trial evaluation for RG3039, Pfizer will assume full responsibility for the SMA program, including any registration trials necessary for product approval.

Email Disclaimer